Blir mer og mer overbevist om at vi kan få en story ala den Moderna fikk med sin AZ deal. Pcib sitter på nøkkelen for å lykkes med mRNA teknologien. Det kan ikke AZ slippe ut av hendene sine. Moderna+AZ+Pcib er det som skal til for å ta et kvantesprang i kreftforsking og i en rekke andre sykdommer.
When AstraZeneca CEO Pascal Soriot made a bet on a little-known Massachusetts-based biotech company back in 2013, he couldn’t have predicted the astonishing success of the investment.
Seven years later, the British drugmaker AZN is sitting on a stake worth more than $2 billion in Moderna Thereapeutics.
Soriot made the $240 million investment in Cambridge-headquartered Moderna to gain access to the startup’s know-how in manipulating RNA, or ribonucleic acid, which helps create proteins inside cells.
The agreement gave AstraZeneca exclusive rights for five years to choose as many as 40 drugs for development. On top of the initial $240 million, Moderna was also entitled to $180 million for achieving certain technical milestones and to payments as well as royalties on drugs developed by AstraZeneca.
In 2016, AstraZeneca invested another $140 million in Moderna, giving it a 9% stake in the Cambridge, Mass. -based company.